Abstracts

CAB-LA PrEP: EARLY DETECTION OF HIV INFECTION MAY REDUCE InSTI RESISTANCE RISK

HPTN 083 and 084 demonstrated that long-acting injectable cabotegravir (CAB-LA) is highly effective for HIV prevention; rare breakthrough infections were observed. Detection of HIV infection in participants who received CAB PrEP was often delayed using standard HIV testing algorithms. In HPTN 083, integrase strand transfer inhibitor (INSTI) resistance-associated mutations (RAMs) were detected in 5 CAB-exposed…

POST-ACUTE SEQUELAE OF SARS-CoV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) is a novel condition generally defined as new onset or persistence of symptoms related to SARS-CoV-2 beyond convalescence or first 30 days post-diagnosis. PASC has not been well defined by conditions or timeline manifestation. We measured PASC incidence in an integrated health system population (Kaiser Permanente Mid-Atlantic States; KPMAS)…

INFLAMMATION, EXERCISE CAPACITY, CHRONOTROPY, AND SYMPTOMS IN POST-ACUTE COVID-19

Cardiopulmonary symptoms and reduced exercise capacity can persist after SARS-CoV-2 infection. Mechanisms of post-acute sequelae of COVID-19 (‘PASC’ or ‘Long COVID’) remain poorly understood. We hypothesized that systemic inflammation would be associated with reduced exercise capacity and pericardial/myocardial inflammation. As part of a COVID recovery cohort (NCT04362150) we assessed symptoms, biomarkers, and echocardiograms in adults…

SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR

Molnupiravir, a prodrug of the broadly active, direct-acting antiviral, ribonucleoside analogue EIDD-1931, is a promising COVID-19 drug. Given the primary route of SARS-CoV-2 transmission through respiratory droplets we evaluated EIDD-1931 PK in saliva, nasal secretions and tears of patients with mild-to-moderate COVID-19 through the phase Ib/IIa AGILE platform (NCT04746183). Patients with PCR-confirmed SARS-CoV-2 infection, within…

CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2

Camostat, a serine protease inhibitor, prevents activation of the SARS-CoV-2 spike protein and blocks SARS-CoV-2 infection in vitro. We studied the safety and antiviral and clinical efficacy of orally administered camostat in non-hospitalized adults with mild-moderate COVID-19. ACTIV-2/A5401 is a platform trial to evaluate therapies for non-hospitalized adults with mild-moderate COVID-19. In a phase 2…